AG13718/AG/NIA NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1998	3
2000	4
2001	2
2003	1
2004	1
2005	1
2007	1
2022	0

1

The interaction of diltiazem with simvastatin.

Mousa O, Brater DC, Sunblad KJ, Hall SD. Mousa O, et al. Clin Pharmacol Ther. 2000 Mar;67(3):267-74. doi: 10.1067/mcp.2000.104609. Clin Pharmacol Ther. 2000. PMID: 10741630 Clinical Trial.

2

Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

Ernest CS 2nd, Hall SD, Jones DR. Ernest CS 2nd, et al. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91. doi: 10.1124/jpet.104.075416. Epub 2004 Nov 2. J Pharmacol Exp Ther. 2005. PMID: 15523003

3

The interaction of diltiazem with lovastatin and pravastatin.

Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. Azie NE, et al. Clin Pharmacol Ther. 1998 Oct;64(4):369-77. doi: 10.1016/S0009-9236(98)90067-4. Clin Pharmacol Ther. 1998. PMID: 9797793 Clinical Trial.

4

The effect of rifampin administration on the disposition of fexofenadine.

Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. Hamman MA, et al. Clin Pharmacol Ther. 2001 Mar;69(3):114-21. doi: 10.1067/mcp.2001.113697. Clin Pharmacol Ther. 2001. PMID: 11240975 Clinical Trial.

5

In vivo effect of clarithromycin on multiple cytochrome P450s.

Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC. Bruce MA, et al. Drug Metab Dispos. 2001 Jul;29(7):1023-8. Drug Metab Dispos. 2001. PMID: 11408369 Clinical Trial.

6

The effect of hormone replacement therapy on CYP3A activity.

Gorski JC, Wang Z, Haehner-Daniels BD, Wrighton SA, Hall SD. Gorski JC, et al. Clin Pharmacol Ther. 2000 Oct;68(4):412-7. doi: 10.1067/mcp.2000.110560. Clin Pharmacol Ther. 2000. PMID: 11061581

7

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. Gorski JC, et al. Clin Pharmacol Ther. 1998 Aug;64(2):133-43. doi: 10.1016/S0009-9236(98)90146-1. Clin Pharmacol Ther. 1998. PMID: 9728893

8

In vivo effects of interleukin-10 on human cytochrome P450 activity.

Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. Gorski JC, et al. Clin Pharmacol Ther. 2000 Jan;67(1):32-43. doi: 10.1067/mcp.2000.103860. Clin Pharmacol Ther. 2000. PMID: 10668851 Clinical Trial.

9

An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

Mayhew BS, Jones DR, Hall SD. Mayhew BS, et al. Drug Metab Dispos. 2000 Sep;28(9):1031-7. Drug Metab Dispos. 2000. PMID: 10950845

10

Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.

Mäenpää J, Hall SD, Ring BJ, Strom SC, Wrighton SA. Mäenpää J, et al. Pharmacogenetics. 1998 Apr;8(2):137-55. Pharmacogenetics. 1998. PMID: 10022752

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results